New cardiovascular-kidney-metabolic (CKM) syndrome guidance from the American Heart Association (AHA) reflects an important shift in how health care understands chronic disease.
For years, conditions including obesity, type 2 diabetes, cardiovascular disease, and chronic kidney disease have often been discussed, managed and measured separately. The newest CKM framework recognizes a different reality: These conditions are deeply interconnected, driven by many of the same underlying metabolic processes and risk factors.
But perhaps the most important implication of this guidance is not how it categorizes disease, but how it reframes risk. For decades, health care has largely been organized around diagnosing and managing disease after it becomes visible. The attention on CKM points toward a different future, one focused on identifying risk earlier, understanding how conditions interact, and intervening before damage becomes irreversible.
The body doesn’t care whether a physician is a cardiologist, nephrologist, endocrinologist, or hepatologist. Yet health care systems, screening programs, and care pathways have historically been organized around individual diseases and specialties.
As health care embraces a more integrated view of chronic disease, an important question emerges: Do our approaches to risk assessment and screening fully reflect what we now understand about metabolic health? Even as we recognize that chronic diseases are interconnected, many assessment strategies still evaluate risk one condition at a time.
Liver health offers a useful example. Far more than a bystander in metabolic disease, the liver is one of its earliest warning signs. Excess fat accumulation in the liver can develop silently for years while contributing to insulin resistance and increasing the risk of type 2 diabetes, cardiovascular disease, and other metabolic complications.
In fact, 7 in 10 people with type 2 diabetes have metabolic dysfunction-associated steatotic liver disease (MASLD). More broadly, 1 in 20 adults has the more advanced form of the disease, metabolic dysfunction-associated steatohepatitis (MASH), yet 9 out of 10 people living with it remain undiagnosed.
Liver disease too often remains absent from routine screening conversations until damage has already progressed. Without proactive assessment, clinicians may miss one of the earliest indicators that metabolic dysfunction is taking hold. Patients can appear healthy while liver injury advances, delaying opportunities to intervene before more serious complications develop.
Consider a patient with obesity, elevated blood sugar, declining kidney function, and no visible symptoms of liver disease. These findings are often interconnected, reflecting underlying metabolic dysfunction that can affect multiple organs simultaneously.
The challenge is not simply identifying each condition. It is understanding what they reveal collectively about a patient’s long-term risk. Looking at obesity, diabetes, kidney disease, or liver disease in isolation can leave clinicians with an incomplete picture of metabolic health. Instead of asking whether a patient has heart disease, kidney disease, diabetes or liver disease, perhaps the better question is this: What risks are emerging today that will shape that patient’s health tomorrow?
Attention given to CKM syndrome reflects a growing recognition that chronic disease is interconnected. The opportunity now is to use that understanding to identify risk earlier and intervene sooner, including in organs such as the liver, where disease can progress silently for years before symptoms appear.
After all, metabolic disease rarely develops one organ at a time.
Jon Gingrich is the CEO of Echosens North America, manufacturer of FibroScan and its VCTE elastography system, the leading non-invasive solution for the comprehensive management of liver health.
